Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis

Abstract

The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent. In the invention the 2,5-dihydroxybenzene sulfonic acid compounds or pharmaceutically acceptable salts thereof are 2,5-dihydroxybenzene sulfonic acid, calcium 2,5-dihydroxybenzenesulfonate, potassium 2,5-dihydroxybenzenesulfonate, magnesium 2,5-dihydroxybenzenesulfonate and diethylamine 2,5-dihydroxybenzenesulfonate.

1 . A method for treating a skin cancer; treating cancer of an organ; treating leukemia; improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salts thereof: 
 wherein the compound of Formula (I) is:                          wherein:    X is a hydrogen, an organic cation or an inorganic cation;    n is an integer from 1 to 2; and    m is an integer from 1 to 2.    
   
   
       2 . The method of  claim 1 , further comprising administering a pharmaceutically acceptable carrier.  
   
   
       3 . The method of  claim 1 , wherein the compound of Formula (I) is selected from the group consisting of: 
 2,5-dihydroxybenzene sulfonic acid;    calcium 2,5-dihydroxybenzenesulfonate;    potassium 2,5-dihydroxybenzenesulfonate;    magnesium 2,5-dihydroxybenzenesulfonate; and    diethylamine 2,5-dihydroxybenzenesulfonate.    
   
   
       4 . The method of  claim 1 , further comprising at least one therapeutic agent.  
   
   
       5 . The method of  claim 4 , wherein the therapeutic agent is a chemotherapeutic agent, a steroid, a retinoid, an antimicrobial compound, an antioxidant, an anti-inflammatory compound, a NMDA receptor antagonist, an endothelin antagonist, an immunomodulating agent, a vitamin D analogue, salicylic acid, or a combination of two or more thereof.  
   
   
       6 . The method of  claim 5 , wherein the therapeutic agent is selected from the group consisting of a chemotherapeutic agent, a steroid, an antimicrobial compound, an antioxidant, an anti-inflammatory compound, a NMDA receptor antagonist, an endothelin antagonist and an immunomodulating agent.  
   
   
       7 . The method of  claim 1 , wherein the skin cancer is basal cell cacinoma, squamous cell carcinoma, a melanoma, a keratoacanthoma, an actinic keratosis, a Bowen's disease verrucae, sarcomas orangiosarcoma.  
   
   
       8 . The method of  claim 1 , wherein the compound of Formula (I) is administered orally, bucally, parenterally, by inhalation, by topical application or rectally.  
   
   
       9 . A method for treating rosacea in a patient in need thereof comprising topically administering to the patient a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salts thereof: 
 wherein the compound of Formula (I) is:                          wherein:    X is a hydrogen, an organic cation or an inorganic cation;    n is an integer from 1 to 2; and    m is an integer from 1 to 2.    
   
   
       10 . The method of  claim 9 , further comprising administering a pharmaceutically acceptable carrier.  
   
   
       11 . The method of  claim 9 , wherein the compound of Formula (I) is selected from the group consisting of: 
 2,5-dihydroxybenzene sulfonic acid;    calcium 2,5-dihydroxybenzenesulfonate;    potassium 2,5-dihydroxybenzenesulfonate;    magnesium 2,5-dihydroxybenzenesulfonate; and    diethylamine 2,5-dihydroxybenzenesulfonate.    
   
   
       12 . The method of  claim 9 , further comprising at least one therapeutic agent.  
   
   
       13 . The method of  claim 12 , wherein the therapeutic agent is a chemotherapeutic agent, a steroid, a retinoid, an antimicrobial compound, an antioxidant, an anti-inflammatory compound, a NMDA receptor antagonist, an endothelin antagonist, an immunomodulating agent, a vitamin D analogue, salicylic acid, or a combination of two or more thereof.  
   
   
       14 . The method of  claim 13 , wherein the therapeutic agent is selected from the group consisting of a steroid, a retinoid, an antimicrobial compound, an antioxidant, an anti-inflammatory compound, a vitamin D analogue and salicylic acid.  
   
   
       15 . A method for treating psoriasis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salts thereof and at least one therapeutic agent: 
 wherein the compound of Formula (I) is:                          wherein:    X is a hydrogen, an organic cation or an inorganic cation;    n is an integer from I to 2; and    m is an integer from 1 to 2.    
   
   
       16 . The method of  claim 15 , further comprising administering a pharmaceutically acceptable carrier.  
   
   
       17 . The method of  claim 15 , wherein the compound of Formula (I) is selected from the group consisting of: 
 2,5-dihydroxybenzene sulfonic acid;    calcium 2,5-dihydroxybenzenesulfonate;    potassium 2,5-dihydroxybenzenesulfonate;    magnesium 2,5-dihydroxybenzenesulfonate; and    diethylamine 2,5-dihydroxybenzenesulfonate.    
   
   
       18 . The method of  claim 15 , wherein the therapeutic agent is a chemotherapeutic agent, a steroid, a retinoid, an antimicrobial compound, an antioxidant, an anti-inflammatory compound, a NMDA receptor antagonist, an endothelin antagonist, an immunomodulating agent, a vitamin D analogue, salicylic acid, or a combination of two or more thereof.  
   
   
       19 . The method of  claim 18 , wherein the therapeutic agent is selected from the group consisting of a steroid, a retinoid, an antimicrobial compound, an antioxidant, an anti-inflammatory compound, a Vitamin D analogue and salicylic acid.  
   
   
       20 . The method of  claim 15 , wherein the compound of Formula (I) and the therapeutic agent are administered orally, bucally, parenterally, by inhalation, by topical application or rectally.